Are AndroGel (testosterone gel) and AndroFeme (testosterone gel) the same medication?

Are AndroGel and AndroFeme the Same Medication?

No, AndroGel and AndroFeme are not the same product—they are distinct testosterone gel formulations marketed under different brand names, with AndroGel approved for male hypogonadism and AndroFeme specifically formulated and approved for postmenopausal women with hypoactive sexual desire disorder (HSDD).

Key Differences Between the Two Products

Approved Indications and Target Populations

• AndroGel is FDA-approved exclusively for testosterone replacement therapy in adult men with hypogonadism (low testosterone due to primary or secondary testicular failure). 1, 2
• AndroFeme is approved for postmenopausal women with HSDD after comprehensive biopsychosocial assessment; this is the only evidence-based indication for testosterone therapy in women. 3

Formulation and Concentration

• AndroGel is a 1% testosterone gel delivering 50 mg, 75 mg, or 100 mg of testosterone per application (5 g, 7.5 g, or 10 g of gel, respectively), with approximately 10% absorbed systemically over 24 hours. 1, 2
• AndroFeme is formulated at a much lower concentration designed to deliver approximately 5 mg of testosterone daily to achieve mid-to-high premenopausal female testosterone levels (≈30–50 ng/dL), which is roughly one-tenth the male dose. 3

Dosing and Application

• AndroGel for men: Apply 5–10 g of gel (50–100 mg testosterone) once daily to shoulders, upper arms, or abdomen to achieve male physiologic testosterone levels of 300–1,000 ng/dL. 2, 4
• AndroFeme for women: Apply approximately 5 mg of testosterone gel daily to the upper arm or outer thigh, targeting serum total testosterone of 30–50 ng/dL—far below male physiologic levels. 3

Pharmacokinetics and Absorption

• Both products use hydroalcoholic gel formulations that dry quickly on the skin and provide sustained transdermal testosterone delivery over 24 hours. 1, 2
• AndroGel achieves steady-state serum testosterone within 24–48 hours in men, with levels maintained in the eugonadal range (298–1,043 ng/dL) throughout daily dosing. 2
• AndroFeme is designed to restore testosterone to premenopausal female levels, not male levels, and requires initial monitoring at 3–6 weeks to confirm appropriate absorption. 3

Clinical Context: Off-Label Use of Male Formulations in Women

• When female-specific testosterone products like AndroFeme are unavailable, off-label use of male-approved transdermal gels (such as AndroGel) at reduced doses is acceptable provided serum testosterone remains within the physiologic female range. 3
• The critical safety requirement is dose reduction: approximately one-tenth of the male dose (≈5 mg daily) must be used to avoid supraphysiologic testosterone levels and virilization (acne, hirsutism, voice deepening, clitoromegaly). 3
• Compounded "bioidentical" testosterone preparations should be avoided unless no authorized equivalent exists, because efficacy and safety data are insufficient and pharmacy-to-pharmacy quality control is inconsistent. 3

Monitoring Requirements Differ by Sex

For Men Using AndroGel

• Measure serum testosterone at 3–6 months, targeting mid-normal range (400–700 ng/dL); check hematocrit at baseline, 3–6 months, and annually; obtain baseline PSA and digital rectal exam in men ≥40 years, then repeat PSA at 3–6 months and annually. 4, 5
• Discontinue therapy immediately if hematocrit exceeds 54%; refer to urology if PSA rises >1.4 ng/mL within 12 months or PSA velocity >0.4 ng/mL per year. 4, 5

For Women Using AndroFeme (or Off-Label Male Gel at Reduced Dose)

• Measure total testosterone 3–6 weeks after starting therapy to confirm absorption and guide dose adjustment, targeting 30–50 ng/dL; repeat every 6 months to detect overuse and ensure levels stay within the physiologic premenopausal range. 3
• At each follow-up, assess for signs of androgen excess (acne, hirsutism, voice deepening, clitoromegaly); discontinue if no clinical benefit in sexual function is observed by 6 months. 3
• Routine hematocrit monitoring is not required for women receiving physiologic-dose testosterone, unlike in male patients. 3

Common Pitfalls to Avoid

• Do not use AndroGel at typical male doses (50–100 mg daily) in women; this yields supraphysiologic testosterone levels and raises the risk of irreversible virilization. 3
• Do not prescribe testosterone for women for indications other than HSDD (e.g., bone health, cognition, energy, well-being), as efficacy and long-term safety are unproven. 3
• Do not continue therapy beyond 6 months without documented improvement in sexual function; prolonged exposure without benefit is unjustified. 3